ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Senores delivered record quarterly revenue and EBITDA, driven by US portfolio expansion and regulated market growth.
Senores Pharmaceuticals reported no deviation in utilising the Rs 95 Crore raised via a preferential warrant issue for the quarter ended September 30, 2026. Audit Committee reviewed the statement and the Board took it on record.
Senores Pharmaceuticals' subsidiary Apnar Pharma Private Limited plans a 0.7 Bn unit capacity addition by March 2027. The investment is Rs.20.00 Crore, funded by internal accruals and IPO proceeds.
Senores Pharmaceuticals plans to add 0.8 Bn units of capacity to its existing 1.2 Bn unit plant by March 2027. The investment is Rs.18.00 Crore, funded by internal accruals and IPO proceeds.
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Senores reported Q2 FY27 revenue of ₹192 cr and EBITDA of ₹58 cr, both record highs. PAT grew 22% Y-o-Y to ₹37 cr with positive FY27 outlook.
Senores Pharmaceuticals disclosed capacity expansion at three subsidiaries with total estimated cost of ₹43 Crore. Expansions adding ~1.5 Bn units/annum are expected by March 2027.
Senores Pharmaceuticals Ltd reported revenue from operations of ₹192.3 Cr (+25.0% YoY) and net profit of ₹36.6 Cr (+21.6% YoY) for Q2 FY27.
Senores Pharmaceuticals has scheduled a board meeting for October 29, 2026, to approve its unaudited financial results for the quarter and half-year ended September 30, 2026.
Senores Pharmaceuticals Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Whole Time Director. The e-voting period concludes on November 17, 2026.
Senores Pharmaceuticals re-appointed Swapnil Shah as MD and Chetan Shah as WTD for three-year terms. Both appointments are subject to shareholder approval via postal ballot.
Senores Pharmaceuticals submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026, as required by SEBI regulation 76.
Senores Pharmaceuticals held its 9th Annual General Meeting on September 25, 2026. Shareholders approved financial statements, director appointments, and the new Employee Stock Option Scheme 2026.
Senores Pharmaceuticals informed exchanges there is no undisclosed or price-sensitive information behind the volume spike. The company affirmed compliance with SEBI LODR disclosure obligations.
Senores Pharmaceuticals Ltd submitted its shareholding pattern for the quarter ended 31 March 2026, in compliance with SEBI regulation 31(1)(b).